alexa
Reach Us +1-217-403-9671
Editor - David William Boulton | Bristol-Myers Squibb & Company | 12946
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

David William Boulton

David William Boulton
David William Boulton
Group Director
Clinical & Translational Research
Bristol-Myers Squibb & Company
New Jersey

Biography

David William Boulton was Undergraduate Pharmacy Student in School of Medicine, University of Otago from Mar 1988 - Nov 1991,Intern Pharmacist in Shirley Pharmacy Limited, Christchurch, NZ from Nov 1991 - Dec 1992 , Research Assistant for “Literature evaluation and experimental assessment of an HPLC assay for levothyroxine and its breakdown products in tablets” supervised by J Paul Fawcett, PhD from Dec 1992 - Feb 1993, Teaching Assistant and Graduate Student in University of Otago from Mar 1993 - Sep 1996, Poisons and Hazardous Chemicals Information Officer from Mar 1993 - Feb 1997, Clinical Trials Research Assistant at at Zentech Inc, Dunedin, New Zealand from Apr 1996 - Feb 1997, Postdoctoral Fellow in Medical University of South Carolina from Mar 1997 - Feb 1998, Postdoctoral Fellow in Medical University of South Carolina, Charleston, SC from Feb 1998 – Jan 2001, Research Investigator II and Senior Research Investigator in BMS from Feb 2001 – may 2005, Associate Director,. Clinical Pharmacologist, CV/Met, Clinical Discovery, BMS from May 2005 - Aug 2008, Director of BMS from Aug 2008 - Aug 2013, Group Director of Bristol-Myers Squibb & Company (BMS) from Aug 2013 - present.

Research Interest


Clinical Pharmacology/Pharmacokinetics, Cardiovascular Disease, Neuroscience, pre-Phase 2b diabetes, Pharmacometricians.

Certificate

Certificate

Global Speakers in the subject

Global Experts in the subject

Pharmaceutical Regulatory Affairs: Open Access - PHARMACOKINETICS


David William Boulton was Undergraduate Pharmacy Student in School of Medicine, University of Otago from Mar 1988 - Nov 1991,Intern Pharmacist in Shirley Pharmacy Limited, Christchurch, NZ from Nov 1991 - Dec 1992 , Research Assistant for “Literature evaluation and experimental assessment of an HPLC assay for levothyroxine and its breakdown products in tablets” supervised by J Paul Fawcett, PhD from Dec 1992 - Feb 1993, Teaching Assistant and Graduate Student in University of Otago from Mar 1993 - Sep 1996, Poisons and Hazardous Chemicals Information Officer from Mar 1993 - Feb 1997, Clinical Trials Research Assistant at at Zentech Inc, Dunedin, New Zealand from Apr 1996 - Feb 1997, Postdoctoral Fellow in Medical University of South Carolina from Mar 1997 - Feb 1998, Postdoctoral Fellow in Medical University of South Carolina, Charleston, SC from Feb 1998 – Jan 2001, Research Investigator II and Senior Research Investigator in BMS from Feb 2001 – may 2005, Associate Director,. Clinical Pharmacologist, CV/Met, Clinical Discovery, BMS from May 2005 - Aug 2008, Director of BMS from Aug 2008 - Aug 2013, Group Director of Bristol-Myers Squibb & Company (BMS) from Aug 2013 - present.

 
Download PPT PPT Views: 180 Updated on: 2015-10-19 For Recent Update: Click here
 
 
Download PDF   PDF Views: 180  Updated on: 2015-10-19 For Recent Update: Click here
 
Top